Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Non-Current Debt (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Non-Current Debt for 3 consecutive years, with $8.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Debt changed N/A to $8.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.4 million, a N/A change, with the full-year FY2020 number at $423000.0, changed N/A from a year prior.
  • Non-Current Debt was $8.4 million for Q3 2025 at Vivos Therapeutics, up from $7.8 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $8.4 million in Q3 2025 to a low of $105906.0 in Q1 2021.